CytoHub
CytoHub is a pioneering developer of intelligent technologies for cell therapy and regenerative medicine, with a focus on accelerating regenerative medicine and empowering cell & gene therapy with AI. The company is dedicated to transforming cell therapy development, process optimization, and biomanufacturing through innovative solutions, AI-driven platforms, and strategic partnerships. Their mission is to revolutionize drug screening, disease modeling, and clinical applications in heart muscle regeneration, aiming to craft cells for cures and advance scientific research in regenerative medicine.
Industries
Nr. of Employees
small (1-50)
CytoHub
3210 Merryfield Row, San Diego, CA 92121, USA
Products
Human mini-heart in vitro model
Complex cardiac in vitro model containing multiple cardiac and supporting cell types to emulate human heart cellular composition for drug screening and disease modeling.
AI-powered scale-up solution
AI-enabled scale-up/scale-down solution to identify and optimize critical process parameters for phase-appropriate manufacturing ramp.
Vascularized cardiac tissue models
Vascularized cardiac constructs intended for drug discovery, disease modeling, and regenerative medicine research.
AI/ML bioprocess analytics platform
Platform for multi-modal data ingestion, modeling and visualization to support protocol optimization, image/video analysis, and knowledge-base expansion for CMC and discovery applications.
Human mini-heart in vitro model
Complex cardiac in vitro model containing multiple cardiac and supporting cell types to emulate human heart cellular composition for drug screening and disease modeling.
AI-powered scale-up solution
AI-enabled scale-up/scale-down solution to identify and optimize critical process parameters for phase-appropriate manufacturing ramp.
Vascularized cardiac tissue models
Vascularized cardiac constructs intended for drug discovery, disease modeling, and regenerative medicine research.
AI/ML bioprocess analytics platform
Platform for multi-modal data ingestion, modeling and visualization to support protocol optimization, image/video analysis, and knowledge-base expansion for CMC and discovery applications.
Services
Optimization of critical process parameters for iPSC-based, autologous, and allogeneic therapies using DOE, process analytics, and suspension/adherent culture strategies.
Development of in vitro assays that replicate in vivo biology including iPSC-derived organoids, organoids-on-chip, primary cell assays, and 3D culture models.
Scale-up services for suspension and adherent cultures, protocol optimization for MCB thaw and aggregate control, and CMC-focused process advancement toward commercialization.
Comprehensive analytical assays for cell therapies including flow cytometry, omics pipelines, cell-based HTS, reporter assays and potency testing.
Support for CMO selection and management, direct transfer of processes to manufacturing partners, and preparation of SOPs, batch records and video documentation plus CMC/regulatory advice.
Development and characterization of cell lines, master cell bank creation, optimized cryopreservation, real-time monitoring and extensive characterization (identity, potency, stability).
Optimization of critical process parameters for iPSC-based, autologous, and allogeneic therapies using DOE, process analytics, and suspension/adherent culture strategies.
Development of in vitro assays that replicate in vivo biology including iPSC-derived organoids, organoids-on-chip, primary cell assays, and 3D culture models.
Scale-up services for suspension and adherent cultures, protocol optimization for MCB thaw and aggregate control, and CMC-focused process advancement toward commercialization.
Comprehensive analytical assays for cell therapies including flow cytometry, omics pipelines, cell-based HTS, reporter assays and potency testing.
Support for CMO selection and management, direct transfer of processes to manufacturing partners, and preparation of SOPs, batch records and video documentation plus CMC/regulatory advice.
Development and characterization of cell lines, master cell bank creation, optimized cryopreservation, real-time monitoring and extensive characterization (identity, potency, stability).
Expertise Areas
- Cell therapy process development
- Biomanufacturing scale-up and CMC optimization
- iPSC-derived organoids and 3D culture models
- Organoids-on-chip and microfluidic systems
Key Technologies
- Induced pluripotent stem cell (iPSC) organoids
- 3D cell culture and suspension culture
- Organoid-on-chip (microfluidics)
- CRISPR-Cas9 gene editing
News & Updates
CytoHub announced the addition of industry experts including Dr. Anand Giddabasappa, Abbas Hashmi, Mohammad El-Kalay, PhD, Richard J. Anderson, Ph.D., and Aitor Aguirre, Ph.D., to its team to advance AI-powered cell therapy platforms and regenerative medicine.
CytoHub announced the addition of industry experts including Dr. Anand Giddabasappa, Abbas Hashmi, Mohammad El-Kalay, PhD, Richard J. Anderson, Ph.D., and Aitor Aguirre, Ph.D., to its team to advance AI-powered cell therapy platforms and regenerative medicine.